Evidence map›Paper›PMID 42222031›Full record

ArticleInfection and drug resistance2026

Stepwise PEG Precipitation Coupled with Hydrophobic Interaction Chromatography Enables the Production of Highly Specific Anti-Ag85B IgY for Tuberculosis Immunodiagnostics.

Meti Kusmiati, Shabarni Gaffar, Sri Agung Fitri Kusuma

Abstract read
In one paragraph

Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Meti KusmiatiDoctoral Program in Pharmacy, Faculty of Pharmacy, University of Padjadjaran, Sumedang, West Java, Indonesia.
Shabarni GaffarDepartment of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Sumedang, Indonesia.ORCID 0000-0002-3659-4774
Sri Agung Fitri KusumaDepartment of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang, West Java, Indonesia.ORCID 0000-0001-8342-0112

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Reliable antigen detection in tuberculosis (TB) immunoassays requires antibodies with high specificity and minimal background interference. Chicken egg yolk immunoglobulin Y (IgY) is a scalable and cost-effective antibody source; however, crude yolk extracts often show reduced specificity due to non-target proteins. Although antigen 85B (Ag85B) is a well-established Methods: Chickens were immunized with recombinant Ag85B, and antibody development was monitored using agar gel precipitation tests (AGPT) with serum collected before and after immunization. Dot blot analysis verified the transfer of anti-Ag85B antibodies from serum to egg yolk prior to IgY extraction. IgY was extracted using either stepwise polyethylene glycol (PEG) precipitation or a NaCl-based water-dilution method, followed by hydrophobic interaction chromatography and centrifugal ultrafiltration. Results: SDS-PAGE demonstrated progressive IgY enrichment and contaminant removal, with PEG extraction yielding higher purity than NaCl-based extraction. Western blot analysis confirmed a distinct immunoreactive band for Ag85B-His with no cross-reactivity against the non-target Conclusion: These findings demonstrate that systematic purification improves IgY specificity and supports the preliminary development of membrane-based proof-of-concept immunodetection systems using Ag85B-specific IgY.

Indexed as

Ag85B-Hisdiagnosticsegg yolkimmunoglobulin YMycobacterium tuberculosisPEG precipitation

Identifiers

PMID42222031
PMCPMC13221440

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.